Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

328
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
328
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

329
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
329
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

252
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
252
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.6K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.6K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

279
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
279
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Living-Donor Kidney Transplantation Between Mother and Son With Clinically Confirmed Hereditary Angioedema.

Pediatric transplantation·2026
Same author

[A machine learning diagnostic model for hereditary hearing loss based on <i>GJB2</i> and <i>SLC26A4 g</i>enes: construction and interpretability analysis].

Zhonghua yi xue za zhi·2026
Same author

[Clinicopathological and genetic analysis of six cases with cherubism].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2026
Same author

[Hearing phenotype and genotypic characteristics in GSDME-related deafness pedigrees].

Zhonghua yi xue za zhi·2026
Same author

[Genomic profiles of primary and acquired MET mutations in NSCLC and the impact of co-mutations on treatment outcomes].

Zhonghua yi xue za zhi·2025
Same author

[A retrospective cohort study on the risk of pulmonary tuberculosis incidence among individuals with latent tuberculosis infection in schools].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025

Related Experiment Video

Updated: Feb 13, 2026

P50 Sensory Gating in Infants
12:55

P50 Sensory Gating in Infants

Published on: December 26, 2013

9.6K

Eculizumab Dosing in Infants.

M Kobrzynski1, B Wile1, S S Huang2

  • 1Department of Pediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Indian Journal of Nephrology
|March 9, 2018
PubMed
Summary

Eculizumab is recommended for atypical hemolytic uremic syndrome (aHUS). Current dosing needs refinement for children, especially infants, to optimize treatment and minimize adverse events.

Keywords:
Atypical hemolytic uremic syndromebiologicdosingeculizumabpediatrics

More Related Videos

Author Spotlight: Marmoset Research - Scope and Challenges
04:52

Author Spotlight: Marmoset Research - Scope and Challenges

Published on: June 9, 2023

2.7K
Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

9.7K

Related Experiment Videos

Last Updated: Feb 13, 2026

P50 Sensory Gating in Infants
12:55

P50 Sensory Gating in Infants

Published on: December 26, 2013

9.6K
Author Spotlight: Marmoset Research - Scope and Challenges
04:52

Author Spotlight: Marmoset Research - Scope and Challenges

Published on: June 9, 2023

2.7K
Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

9.7K

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Eculizumab is the standard treatment for atypical hemolytic uremic syndrome (aHUS).
  • Existing dosing guidelines are based on limited data from retrospective and prospective trials.
  • Pediatric populations, particularly infants, represent a significant challenge for current dosing protocols.

Observation:

  • A case report identified potential issues with current eculizumab dosing in pediatric aHUS patients.
  • The study highlights variability in clinical response and potential for adverse events.
  • Current vial sizes may hinder precise dose adjustments in infants and small children.

Findings:

  • Current eculizumab dosing recommendations may not be optimal for pediatric patients, especially infants.
  • There is a need for more precise dosing strategies tailored to pediatric weight and age.
  • Smaller vial sizes could improve dose accuracy and reduce medication waste.

Implications:

  • Revised dosing guidelines for eculizumab in children are necessary.
  • Development of smaller vial formulations could enhance pediatric aHUS treatment.
  • Optimized dosing will improve clinical outcomes and safety for children with aHUS.